New Recheck Option Expands IDPPID Testing Program to Support Ongoing Management

With an estimated 21% of horses over the age of 15 affected by pituitary pars intermedia dysfunction (PPID),¹ ongoing monitoring plays a critical role in managing this progressive condition. To further support veterinarians in evaluating treatment response, Boehringer Ingelheim has added a recheck component to its IDPPID testing program.

Starting with the current spring 2026 testing period, eligible horses newly diagnosed with PPID and undergoing treatmentwith PRASCEND® (pergolide tablets) may be reevaluated through the program. This update enables veterinarians to assess changes in endocrine health alongside clinical signs, helping inform next steps in disease management. Veterinarians can contact their Boehringer territory manager with questions or for more information.

“PPID is a progressive disease,” says Steve Grubbs, DVM, PhD, DACVIM, Technical Manager, Equine, Boehringer Ingelheim. “By offering a recheck, we are providing veterinarians with additional valuable information to help guide treatment protocols, while continuing to build our understanding of PPID and its progression.”

Since the IDPPID program’s inception in 2013, more than 65,000 horses have been tested,² resulting in horses being diagnosed and subsequently treated for PPID.

Besides rechecking horses with PPID via adrenocorticotropic hormone (ACTH), insulin and glucose testing, Dr. Grubbs recommends continuing to monitor changes in clinical signs observed at initial diagnosis. These signs can include changes in attitude, decreased performance, delayed hair coat shedding and loss of topline muscle in the early stages. If the condition is more advanced, recurrent infections, exercise intolerance and generalized muscle atrophy may be present.

The spring testing period is currently open through June 9, 2026. The fall testing period runs Aug. 18-Oct. 13. For more details, visit IDPPID.com.

IMPORTANT SAFETY INFORMATION:

PRASCEND treatment may cause loss of appetite. Most cases are mild. Adverse reactions may occur if animals other than horses ingest PRASCEND tablets. Not for human use. Do not ingest the product. Refer to the package insert for complete product information.

References

1. Grubbs ST, Neal DL and Keefe TJ. Epidemiological characteristics of horses with PPID at initial diagnosis. Boehringer Ingelheim Animal Health USA Inc., St. Joseph, Mo., and Colorado State University, Fort Collins, Co. 2020.
2. IDPPID Testing Program, 2013-2025. Data on file.

About Boehringer Ingelheim Animal Health

Boehringer Ingelheim provides innovation for preventing and treating diseases in animals. The company offers a wide range of vaccines, parasite-control products and medicines for pets, horses and livestock to veterinarians, animal owners, farmers and governments. As a leader in animal health, Boehringer Ingelheim values that the health of humans and animals is deeply connected, and strives to make a difference for people, animals and society. Learn more at www.boehringer-ingelheim.com/us/animal-health.

About Boehringer Ingelheim

Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry’s top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. Our approximately 54,500 employees serve over 130 markets to build a healthier and more sustainable tomorrow. Learn more at www.boehringer-ingelheim.com.

Stay in the know! Sign up for EquiManagement’s FREE weekly newsletters to get the latest equine research, disease alerts, and vet practice updates delivered straight to your inbox.